Long-Term Efficacy and Safety of Ipragliflozin plus Insulin in Japanese Patients with Type 2 Diabetes (IOLITE)

被引：0
|
作者：
Ishihara, Hisamitsu
Yamaguchi, Susumu
Nakao, Ikko
Okitsu, Akira
Asahina, Seitaro
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1250-P
引用
收藏
页码：A335 / A335
页数：1
相关论文
共 50 条
  • [1] Long-Term Safety, Tolerability and Efficacy of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus: IGNITE
    Kawano, Hiromichi
    Kashiwagi, Atsunori
    Kazuta, Kenichi
    Yoshida, Satoshi
    Ueyama, Eiji
    Utsuno, Atsushi
    DIABETES, 2012, 61 : A610 - A610
  • [2] Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
    Inagaki, Nobuya
    Harashima, Shin-ichi
    Kaku, Kohei
    Kondo, Kazuoki
    Maruyama, Nobuko
    Otsuka, Makiko
    Kawaguchi, Yutaka
    Iijima, Hiroaki
    DIABETES OBESITY & METABOLISM, 2018, 20 (04): : 812 - 820
  • [3] Efficacy and Safety of Long-Term Administration of Dapagliflozin for Japanese Patients with Type 2 Diabetes Mellitus
    Yamazaki, Masahiro
    Sakai, Ryosuke
    Okamura, Takuro
    Fukui, Michiaki
    DIABETES, 2018, 67
  • [4] Efficacy and Safety of Ipragliflozin in Japanese Type 2 Diabetic Patients
    Takihata, Masahiro
    Terauchi, Yasuo
    DIABETES, 2015, 64 : A311 - A311
  • [5] Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study
    Shimoda, Masashi
    Mashiko, Akiko
    Katakura, Yukino
    Sanada, Junpei
    Fushimi, Yoshiro
    Obata, Atsushi
    Kimura, Tomohiko
    Kohara, Kenji
    Tatsumi, Fuminori
    Nakanishi, Shuhei
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    ENDOCRINE JOURNAL, 2021, 68 (12) : 1455 - 1461
  • [6] Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
    Thuillier, Philippe
    Alavi, Zarrin
    Kerlan, Veronique
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 483 - 492
  • [7] Efficacy and safety of SGLT2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes
    Nomiyama, Takashi
    Tanabe, Makito
    Murase, Kunitaka
    Motonaga, Ryoko
    Yanase, Toshihiko
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S93 - S93
  • [8] Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
    Kaku, Kohei
    Kadowaki, Takashi
    Seino, Yutaka
    Okamoto, Taro
    Shirakawa, Masayoshi
    Sato, Asako
    O'Neill, Edward A.
    Engel, Samuel S.
    Kaufman, Keith D.
    DIABETES OBESITY & METABOLISM, 2021, 23 (09): : 2099 - 2108
  • [9] Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes
    Araki, E.
    Kawamori, R.
    Inagaki, N.
    Watada, H.
    Hayashi, N.
    Horie, Y.
    Sarashina, A.
    Thiemann, S.
    von Eynatten, M.
    Dugi, K.
    Woerle, H. -J.
    DIABETES OBESITY & METABOLISM, 2013, 15 (04): : 364 - 371
  • [10] Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study
    Ishihara, Hisamitsu
    Yamaguchi, Susumu
    Nakao, Ikko
    Okitsu, Akira
    Asahina, Seitaro
    DIABETES OBESITY & METABOLISM, 2016, 18 (12): : 1207 - 1216
12345